← Back to Search

PET Imaging for Parkinson's Disease

Phase < 1
Recruiting
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Hoehn and Yahr stage I-IV
Have an existing diagnosis of idiopathic PD, using consensus criteria
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up tp 120 minutes
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to test the use of a radioactive substance called [11C]SY08 with PET imaging to detect a protein called alpha synuclein in people with Parkinson's disease, multiple system at

Who is the study for?
This trial is for individuals aged 50-80 with Parkinson's Disease, Multiple System Atrophy, or Lewy Body Dementia. Participants must be able to consent, speak English, and have a partner to assist with assessments. They should be on stable medications for at least 30 days.
What is being tested?
[11C]SY08 is being tested as a PET radiotracer in patients with brain alpha-synuclein aggregates and healthy controls. The study will assess how the tracer distributes and moves in the brain after an intravenous injection.
What are the potential side effects?
As this trial involves imaging rather than medication or therapy intervention, side effects are expected to be minimal but may include discomfort from the injection or reactions related to lying still during PET/MRI scanning.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My Parkinson's disease is between stages I and IV.
Select...
I have been diagnosed with Parkinson's disease by a doctor.
Select...
I have been diagnosed with multiple system atrophy (MSA).
Select...
I am between 50 and 80 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up tp 120 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and up tp 120 minutes for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
brain uptake evaluation

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: evaluation of alpha synuclein aggregates in the brainExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
3,026 Previous Clinical Trials
13,413,771 Total Patients Enrolled
26 Trials studying Dementia
202,579 Patients Enrolled for Dementia
~25 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top